Last reviewed · How we verify

NCT05332184

Cardiac T1 Mapping Enables Risk Prediction of LV Dysfunction After Surgery for Aortic Regurgitation

Completed Last updated 18 April 2022
What this trial tests

trial testing aortic valve surgery in Aortic Regurgitation in 40 participants. Completed in 13 March 2020.

Timeline
1 July 2016
Primary endpoint
29 August 2019
13 March 2020

Quick facts

Lead sponsorUniversitätsklinikum Hamburg-Eppendorf
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date1 July 2016
Primary completion29 August 2019
Estimated completion13 March 2020

Drugs / interventions tested

Conditions studied

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

Eligibility, any sex, with Aortic Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess whether cardiac T1 mapping for detection of myocardial fibrosis enables preoperative identification of patients at risk for early left ventricular dysfunction after surgery of aortic regurgitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aortic Regurgitation

Currently open trials in the same condition.

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05332184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing